BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 2020;45:462-71. [PMID: 31733631 DOI: 10.1038/s41386-019-0569-3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Heal DJ, Gosden J, Smith SL, Atterwill CK. Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines. Neuropharmacology 2023;225:109375. [PMID: 36529260 DOI: 10.1016/j.neuropharm.2022.109375] [Reference Citation Analysis]
2 Neumann J, Azatsian K, Höhm C, Hofmann B, Gergs U. Cardiac effects of ephedrine, norephedrine, mescaline, and 3,4-methylenedioxymethamphetamine (MDMA) in mouse and human atrial preparations. Naunyn Schmiedebergs Arch Pharmacol 2023;396:275-87. [PMID: 36319858 DOI: 10.1007/s00210-022-02315-2] [Reference Citation Analysis]
3 Yates JR. Introduction to addiction. Determinants of Addiction 2023. [DOI: 10.1016/b978-0-323-90578-7.00014-1] [Reference Citation Analysis]
4 Holze F, Becker AM, Kolaczynska KE, Duthaler U, Liechti ME. Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. Clin Pharmacol Ther 2022. [PMID: 36507738 DOI: 10.1002/cpt.2821] [Reference Citation Analysis]
5 Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Neurosurgery 2022;Publish Ahead of Print. [DOI: 10.1227/neu.0000000000002275] [Reference Citation Analysis]
6 Bohn A, Kiggen MHH, Uthaug MV, van Oorsouw KIM, Ramaekers JG, van Schie HT. Altered States of Consciousness During Ceremonial San Pedro Use. The International Journal for the Psychology of Religion 2022. [DOI: 10.1080/10508619.2022.2139502] [Reference Citation Analysis]
7 de Sousa GM, de Oliveira Tavares VD, de Menezes Galvão AC, de Almeida RN, Palhano-Fontes F, Lobão-Soares B, de Morais Freire FA, Nunes EA, Maia-de-Oliveira JP, Perkins D, Sarris J, de Araujo DB, Galvão-Coelho NL. Moderators of ayahuasca's biological antidepressant action. Front Psychiatry 2022;13:1033816. [PMID: 36545037 DOI: 10.3389/fpsyt.2022.1033816] [Reference Citation Analysis]
8 Prugger J, Derdiyok E, Dinkelacker J, Costines C, Schmidt TT. The Altered States Database: Psychometric data from a systematic literature review. Sci Data 2022;9:720. [PMID: 36418335 DOI: 10.1038/s41597-022-01822-4] [Reference Citation Analysis]
9 Okano L, Jones G, Deyo B, Brandenburg A, Hale W. Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder. Front Psychiatry 2022;13. [DOI: 10.3389/fpsyt.2022.965641] [Reference Citation Analysis]
10 Bedford P, Hauke DJ, Wang Z, Roth V, Nagy-huber M, Holze F, Ley L, Vizeli P, Liechti ME, Borgwardt S, Müller F, Diaconescu AO. The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity.. [DOI: 10.1101/2022.11.01.514687] [Reference Citation Analysis]
11 Weleff J, Akiki TJ, Barnett BS. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. J Psychoactive Drugs 2022;:1-11. [PMID: 36218281 DOI: 10.1080/02791072.2022.2133757] [Reference Citation Analysis]
12 Alexander Muacevic, John R Adler. The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier? Cureus;14:e30919. [PMID: 36465766 DOI: 10.7759/cureus.30919] [Reference Citation Analysis]
13 Stone BM. A positive psychology framework for why people use substances: Implications for treatment. Front Psychol 2022;13:1017186. [DOI: 10.3389/fpsyg.2022.1017186] [Reference Citation Analysis]
14 Chow TYA, Chan CK, Ng SH, Tse ML. Hong Kong poison information centre: Annual report 2020. Hong Kong Journal of Emergency Medicine 2022. [DOI: 10.1177/10249079221127611] [Reference Citation Analysis]
15 Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 2022. [PMID: 36123427 DOI: 10.1038/s41386-022-01389-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Chen L, Chen W, Pan C, Kuo C, Huang M. Clinical profiles of first-time drug offenders in Taipei City: Comparison of methamphetamine, MDMA, and marijuana users.. [DOI: 10.21203/rs.3.rs-2018218/v1] [Reference Citation Analysis]
17 van Elk M, Yaden DB. Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neurosci Biobehav Rev 2022;140:104793. [PMID: 35878791 DOI: 10.1016/j.neubiorev.2022.104793] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rossi GN, Hallak JEC, Baker G, Dursun SM, Dos Santos RG. The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. Eur Arch Psychiatry Clin Neurosci 2022. [PMID: 35829812 DOI: 10.1007/s00406-022-01460-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Vizeli P, Straumann I, Duthaler U, Varghese N, Eckert A, Paulus MP, Risbrough V, Liechti ME. Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects. Front Pharmacol 2022;13:906639. [DOI: 10.3389/fphar.2022.906639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Front Psychiatry 2022;13:917199. [DOI: 10.3389/fpsyt.2022.917199] [Reference Citation Analysis]
21 Bosch OG, Halm S, Seifritz E. Psychedelics in the treatment of unipolar and bipolar depression. Int J Bipolar Disord 2022;10:18. [PMID: 35788817 DOI: 10.1186/s40345-022-00265-5] [Reference Citation Analysis]
22 Matrenitsky VL. РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ. Lik sprava 2022. [DOI: 10.31640/2706-8803-2022-(3-4)-04] [Reference Citation Analysis]
23 Glowacki DR, Williams RR, Wonnacott MD, Maynard OM, Freire R, Pike JE, Chatziapostolou M. Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-12637-z] [Reference Citation Analysis]
24 de Deus Pontual AA, Senhorini HG, Corradi-Webster CM, Tófoli LF, Daldegan-Bueno D. Systematic Review of Psychometric Instruments Used in Research with Psychedelics. J Psychoactive Drugs 2022;:1-10. [PMID: 35616606 DOI: 10.1080/02791072.2022.2079108] [Reference Citation Analysis]
25 Polito V, Liknaitzky P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955 - 2021) and recommendations for the field. Neurosci Biobehav Rev 2022;:104706. [PMID: 35609684 DOI: 10.1016/j.neubiorev.2022.104706] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Jian-Min C, Zhi-Yuan W, Shi-Xuan W, Rui S, Ning W, Jin L. Effects of Lisdexamfetamine, a Prodrug of D-Amphetamine, on Locomotion, Spatial Cognitive Processing and Neurochemical Profiles in Rats: A Comparison With Immediate-Release Amphetamine. Front Psychiatry 2022;13:885574. [PMID: 35558431 DOI: 10.3389/fpsyt.2022.885574] [Reference Citation Analysis]
27 Lyubomirsky S. Toward a New Science of Psychedelic Social Psychology: The Effects of MDMA (Ecstasy) on Social Connection. Perspect Psychol Sci 2022;:17456916211055369. [PMID: 35536567 DOI: 10.1177/17456916211055369] [Reference Citation Analysis]
28 Mallaroni P, Mason NL, Vinckenbosch FRJ, Ramaekers JG. The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides. Psychopharmacology (Berl) 2022. [PMID: 35487983 DOI: 10.1007/s00213-022-06142-4] [Reference Citation Analysis]
29 Avram M, Müller F, Rogg H, Korda A, Andreou C, Holze F, Vizeli P, Ley L, Liechti ME, Borgwardt S. Characterizing thalamocortical (dys)connectivity following d-amphetamine, LSD, and MDMA administration. Biol Psychiatry Cogn Neurosci Neuroimaging 2022:S2451-9022(22)00096-9. [PMID: 35500840 DOI: 10.1016/j.bpsc.2022.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Pędzich BD, Rubens S, Sekssaoui M, Pierre A, Van Schuerbeek A, Marin P, Bockaert J, Valjent E, Bécamel C, De Bundel D. Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice. Neuropsychopharmacology 2022. [PMID: 35449450 DOI: 10.1038/s41386-022-01324-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Qiu TT, Minda JP. Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing. J Psychoactive Drugs 2022;:1-11. [PMID: 35438609 DOI: 10.1080/02791072.2022.2060773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kloft L, Otgaar H, Blokland A, Toennes SW, Ramaekers JG. Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure. European Neuropsychopharmacology 2022;57:59-68. [DOI: 10.1016/j.euroneuro.2022.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chan G, Sun T, Lim C, Yuen WS, Stjepanović D, Rutherford B, Hall W, Johnson B, Leung J. An age-period-cohort analysis of trends in psychedelic and ecstasy use in the Australian population. Addict Behav 2022;127:107216. [PMID: 34979428 DOI: 10.1016/j.addbeh.2021.107216] [Reference Citation Analysis]
34 Nichols DE. Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated. Front Psychiatry 2022;13:863088. [DOI: 10.3389/fpsyt.2022.863088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Bălăet̨ M. Psychedelic Cognition—The Unreached Frontier of Psychedelic Science. Front Neurosci 2022;16:832375. [DOI: 10.3389/fnins.2022.832375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Kisely S, Connor M, Somogyi AA, Siskind D. A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Aust N Z J Psychiatry 2022;:48674221083868. [PMID: 35285280 DOI: 10.1177/00048674221083868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Family N, Hendricks PS, Williams LT, Luke D, Krediet E, Maillet EL, Raz S. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. J Psychopharmacol 2022;36:321-36. [DOI: 10.1177/02698811211069103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Holze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, Kuehne SS, Roder MA, Duthaler U, Kolaczynska KE, Varghese N, Eckert A, Liechti ME. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 2022. [PMID: 35217796 DOI: 10.1038/s41386-022-01297-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
39 Maples-Keller JL, Norrholm SD, Burton M, Reiff C, Coghlan C, Jovanovic T, Yasinski C, Jarboe K, Rakofsky J, Rauch S, Dunlop BW, Rothbaum BO. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol 2022;:2698811211069124. [PMID: 35166140 DOI: 10.1177/02698811211069124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
40 Poyatos L, Torres A, Papaseit E, Pérez-Mañá C, Hladun O, Núñez-Montero M, de la Rosa G, Torrens M, Fuster D, Muga R, Farré M. Abuse Potential of Cathinones in Humans: A Systematic Review. J Clin Med 2022;11:1004. [PMID: 35207278 DOI: 10.3390/jcm11041004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol 2022;:2698811211069100. [PMID: 35107059 DOI: 10.1177/02698811211069100] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
42 Vollenweider FX, Smallridge JW. Classic Psychedelic Drugs: Update on Biological Mechanisms. Pharmacopsychiatry. [DOI: 10.1055/a-1721-2914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
43 Bender D, Hellerstein DJ. Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology. [DOI: 10.1007/s00213-021-06049-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
44 Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V. Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Front Psychiatry 2021;12:800072. [PMID: 34975593 DOI: 10.3389/fpsyt.2021.800072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
45 Kojic M, Saelens J, Kadriu B, Zarate CA, Kraus C. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. Disruptive Psychopharmacology 2022. [DOI: 10.1007/7854_2022_313] [Reference Citation Analysis]
46 D'aprile I. Main Drugs of Abuse. Encyclopedia of Behavioral Neuroscience, 2nd edition 2022. [DOI: 10.1016/b978-0-12-819641-0.00125-0] [Reference Citation Analysis]
47 Steuer AE. Effects of Amphetamine-Type Stimulants on the Metabolome. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-67928-6_122-1] [Reference Citation Analysis]
48 Fauvel B, Piolino P. La psychothérapie assistée par la MDMA dans la prise en charge du syndrome de stress post-traumatique. Psychologie Française 2021;66:345-56. [DOI: 10.1016/j.psfr.2020.12.003] [Reference Citation Analysis]
49 Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther 2021. [PMID: 34743319 DOI: 10.1002/cpt.2487] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
50 Li H, Zhong Y, Yang S, Wang J, Li X, Xu J, Gao H, Chen G. The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers. Hum Psychopharmacol 2021;:e2825. [PMID: 34739739 DOI: 10.1002/hup.2825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Regan A, Margolis S, de Wit H, Lyubomirsky S. Does ±3,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis. PLoS One 2021;16:e0258849. [PMID: 34695117 DOI: 10.1371/journal.pone.0258849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and Other Psychoplastogens for Treating Mental Illness. Front Psychiatry 2021;12:727117. [PMID: 34671279 DOI: 10.3389/fpsyt.2021.727117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
53 Costa G, Gołembiowska K. Neurotoxicity of MDMA: Main effects and mechanisms. Exp Neurol 2022;347:113894. [PMID: 34655576 DOI: 10.1016/j.expneurol.2021.113894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
54 Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the Potential of Psychedelics for the Treatment of PTSD. Int J Neuropsychopharmacol 2020;23:385-400. [PMID: 32170326 DOI: 10.1093/ijnp/pyaa018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 27.0] [Reference Citation Analysis]
55 Holze F, Caluori TV, Vizeli P, Liechti ME. Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology (Berl) 2021. [PMID: 34515824 DOI: 10.1007/s00213-021-05978-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
56 Poyatos L, Papaseit E, Olesti E, Pérez-Mañá C, Ventura M, Carbón X, Grifell M, Fonseca F, Torrens M, de la Torre R, Farré M. A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure. Biology (Basel) 2021;10:788. [PMID: 34440023 DOI: 10.3390/biology10080788] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
57 Losacker M, Kraemer M, Philipsen A, Duecker K, Dreimueller N, Engelmann J, Roehrich J, Hess C. Enantioselective Quantification of Amphetamine and Metabolites in Serum Samples: Forensic Evaluation and Estimation of Consumption Time. Metabolites 2021;11:521. [PMID: 34436462 DOI: 10.3390/metabo11080521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kolaczynska KE, Thomann J, Hoener MC, Liechti ME. The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative. Int J Mol Sci 2021;22:8277. [PMID: 34361040 DOI: 10.3390/ijms22158277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
59 Holze F, Avedisian I, Varghese N, Eckert A, Liechti ME. Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. Front Pharmacol 2021;12:711255. [PMID: 34326773 DOI: 10.3389/fphar.2021.711255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
60 Vizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME. Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Sci Rep 2021;11:10851. [PMID: 34035391 DOI: 10.1038/s41598-021-90343-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
61 de Abreu MS, Giacomini ACVV, Demin KA, Galstyan DS, Zabegalov KN, Kolesnikova TO, Amstislavskaya TG, Strekalova T, Petersen EV, Kalueff AV. Unconventional anxiety pharmacology in zebrafish: Drugs beyond traditional anxiogenic and anxiolytic spectra. Pharmacol Biochem Behav 2021;207:173205. [PMID: 33991579 DOI: 10.1016/j.pbb.2021.173205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Cleal M, Fontana BD, Parker MO. The cognitive and behavioral effects of D-amphetamine and nicotine sensitization in adult zebrafish. Psychopharmacology (Berl) 2021;238:2191-200. [PMID: 33963883 DOI: 10.1007/s00213-021-05844-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
63 Rocha JM, Rossi GN, de Lima Osório F, Bouso JC, de Oliveira Silveira G, Yonamine M, Campos AC, Bertozi G, Cecílio Hallak JE, Dos Santos RG. Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial. J Clin Psychopharmacol 2021;41:267-74. [PMID: 33843820 DOI: 10.1097/JCP.0000000000001396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
64 Lapostolle F, Beaune S. Ecstasy : la deuxième vague…. Ann Fr Med Urgence 2021;11:100-11. [DOI: 10.3166/afmu-2021-0309] [Reference Citation Analysis]
65 Studerus E, Vizeli P, Harder S, Ley L, Liechti ME. Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies. J Psychopharmacol 2021;35:556-65. [PMID: 33781103 DOI: 10.1177/0269881121998322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
66 Dos Santos RG, Hallak JE, Baker G, Dursun S. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. J Psychopharmacol 2021;35:453-8. [PMID: 33740877 DOI: 10.1177/0269881120986422] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
67 Inserra A, De Gregorio D, Gobbi G. Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacol Rev 2021;73:202-77. [PMID: 33328244 DOI: 10.1124/pharmrev.120.000056] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 14.0] [Reference Citation Analysis]
68 Olson DE. The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci 2021;4:563-7. [PMID: 33861218 DOI: 10.1021/acsptsci.0c00192] [Cited by in Crossref: 60] [Cited by in F6Publishing: 66] [Article Influence: 20.0] [Reference Citation Analysis]
69 Hutten NR, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Feilding A, Ramaekers JG, Kuypers KP. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. European Neuropsychopharmacology 2020;41:81-91. [DOI: 10.1016/j.euroneuro.2020.10.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
70 Thiebot P, Allard M, Boukerma K, Delhotal B, Houze P, Megarbane B, Labat L. Consommation d’ecstasy surdosé : à propos d’un cas mortel. Toxicologie Analytique et Clinique 2020;32:308-314. [DOI: 10.1016/j.toxac.2020.05.003] [Reference Citation Analysis]
71 Kadriu B, Greenwald M, Henter ID, Gilbert JR, Kraus C, Park LT, Zarate CA. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. Int J Neuropsychopharmacol 2021;24:8-21. [PMID: 33252694 DOI: 10.1093/ijnp/pyaa087] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
72 Müller F, Holze F, Dolder P, Ley L, Vizeli P, Soltermann A, Liechti ME, Borgwardt S. MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. Neuropsychopharmacology 2021;46:545-53. [PMID: 33219313 DOI: 10.1038/s41386-020-00906-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
73 Müller F, Mühlhauser M, Holze F, Lang UE, Walter M, Liechti ME, Borgwardt S. Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects. Front Psychiatry 2020;11:573953. [PMID: 33192701 DOI: 10.3389/fpsyt.2020.573953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
74 Holze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Duthaler U, Feilding A, Ramaekers JG, Kuypers KPC. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. Clin Pharmacol Ther 2021;109:658-66. [PMID: 32975835 DOI: 10.1002/cpt.2057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
75 Holze F, Vizeli P, Ley L, Müller F, Dolder P, Stocker M, Duthaler U, Varghese N, Eckert A, Borgwardt S, Liechti ME. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 2021;46:537-44. [PMID: 33059356 DOI: 10.1038/s41386-020-00883-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 20.0] [Reference Citation Analysis]
76 Schmid Y, Gasser P, Oehen P, Liechti ME. Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol 2021;35:362-74. [PMID: 33853422 DOI: 10.1177/0269881120959604] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
77 Oeri HE. Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol 2021;35:512-36. [PMID: 32909493 DOI: 10.1177/0269881120920420] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
78 Steuer AE, Kaelin D, Boxler MI, Eisenbeiss L, Holze F, Vizeli P, Czerwinska J, Dargan PI, Abbate V, Liechti ME, Kraemer T. Comparative Untargeted Metabolomics Analysis of the Psychostimulants 3,4-Methylenedioxy-Methamphetamine (MDMA), Amphetamine, and the Novel Psychoactive Substance Mephedrone after Controlled Drug Administration to Humans. Metabolites 2020;10:E306. [PMID: 32726975 DOI: 10.3390/metabo10080306] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
79 Greenway KT, Garel N, Jerome L, Feduccia AA. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology 2020;13:655-70. [DOI: 10.1080/17512433.2020.1772054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
80 van Mulukom V, Patterson RE, van Elk M. Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism. Psychopharmacology (Berl) 2020;237:2725-37. [PMID: 32472162 DOI: 10.1007/s00213-020-05568-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
81 Ilic M, Holy M, Jaentsch K, Liechti ME, Lubec G, Baumann MH, Sitte HH, Luethi D. Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of In Vitro Methods to Assess the Potency of Drugs That Target Monoamine Transporters. Front Pharmacol 2020;11:673. [PMID: 32508638 DOI: 10.3389/fphar.2020.00673] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
82 Grumann C, Henkel K, Brandt SD, Stratford A, Passie T, Auwärter V. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Test Anal 2020;12:1144-53. [PMID: 32415750 DOI: 10.1002/dta.2821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J Psychopharmacol 2020;34:623-35. [PMID: 32255395 DOI: 10.1177/0269881120909409] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
84 [DOI: 10.1101/19007542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]